Maze Therapeutics, Inc.
For the period ended Sep 30, 2025. Filed Nov 6, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 6, 2025
MAZE$35.45+1.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Operations and Comprehensive (Loss) Income
(In thousands, except share and per share data)
| Three Months Ended September 30, | Nine Months Ended September 30, | |||
|---|---|---|---|---|
| 2025 | 2024 | 2025 | 2024 | |
| License revenue | $— | $2,500 | $— | $167,500 |
| Operating expenses: | ||||
| Research and development | 25,190 | 19,857 | 80,878 | 61,280 |
| General and administrative | 7,775 | 6,872 | 23,962 | 18,908 |
| Total operating expenses | 32,965 | 26,729 | 104,840 | 80,188 |
| (Loss) income from operations | (32,965) | (24,229) | (104,840) | 87,312 |
| Interest and other income, net | 2,878 | 1,846 | 8,288 | 3,138 |
| Change in fair value of convertible promissory notes | — | (2,648) | — | (7,193) |
| (Loss) income before income tax benefit (expense) | (30,087) | (25,031) | (96,552) | 83,257 |
| Income tax benefit (expense) | — | 279 | — | (1,447) |
| Net (loss) income | $(30,087) | $(24,752) | $(96,552) | $81,810 |
| Allocation of undistributed earnings to participating securities (see Note 13) | — | — | — | (73,499) |
| Net (loss) income attributable to common stockholders, basic (see Note 13) | $(30,087) | $(24,752) | $(96,552) | $8,311 |
| Net (loss) income attributable to common stockholders, diluted (see Note 13) | $(30,087) | $(24,752) | $(96,552) | $9,031 |
| Net (loss) income per share attributable to common stockholders (see Note 13): | ||||
| Basic | $(0.66) | $(10.25) | $(2.45) | $3.49 |
| Diluted | $(0.66) | $(10.25) | $(2.45) | $2.67 |
| Weighted-average shares of common stock outstanding used to compute net (loss) income per share attributable to common stockholders (see Note 13): | ||||
| Basic | 45,779,577 | 2,415,897 | 39,464,634 | 2,384,117 |
| Diluted | 45,779,577 | 2,415,897 | 39,464,634 | 3,387,166 |
| Comprehensive income: | ||||
| Net (loss) income | $(30,087) | $(24,752) | $(96,552) | $81,810 |
| Other comprehensive income: | ||||
| Net unrealized gain on marketable securities | 69 | — | 69 | — |
| Comprehensive (loss) income | $(30,018) | $(24,752) | $(96,483) | $81,810 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.